Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Sex Transm Dis. 1995 Sep-Oct;22(5):274-80.

The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women.

Author information

  • 1Epidemiology Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.

Abstract

BACKGROUND AND OBJECTIVES:

Azithromycin, an approved single-dose therapy for cervical chlamydia infections, costs four times as much as doxycycline, the standard multidose theapy.

GOAL OF THIS STUDY:

This study examined whether azithromycin is cost effective for treating cervical chlamydia infections.

STUDY DESIGN:

Two diagnostic strategies were compared: 1) laboratory confirmation of chlamydia, and 2) presumptive diagnosis from the perspective of the healthcare system and the publicly funded clinic.

RESULTS:

From the healthcare perspective, the cost per case of pelvic inflammatory disease prevented with azithromycin ranges from a savings of $3,502 for laboratory confirmation to a cost of $792 for presumptive diagnosis. From the publicly funded clinic perspective, the cost per case of pelvic inflammatory disease prevented ranges from $709 for lab-confirmed diagnosis to $3,969 for presumptive treatment.

CONCLUSION:

For the healthcare system, azithromycin is a cost-effective alternative to doxycycline. However, the cost of azithromycin must decrease markedly for it to be less costly to the publicly funded clinic.

Comment in

PMID:
7502180
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk